WWM
VRDN icon

Wolff Wiese Magana’s Viridian Therapeutics VRDN Stock Holding History

Wolff Wiese Magana’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-38
Closed -$513 – 1050
2025
Q1 		$513 Hold
38
– – ﹤0.01% 916
2024
Q4 		$729 Hold
38
– – ﹤0.01% 850
2024
Q3 		$865 Buy
+38
New +$621 ﹤0.01% 871

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Wolff Wiese Magana's VRDN Position: Q2 2025 in Review

Wolff Wiese Magana sold out of Viridian Therapeutics (VRDN) in Q2 2025, closing a stake of 38 shares — an estimated $513 sold.

Wolff Wiese Magana first reported a position in VRDN in Q3 2024 and held it in 3 quarters. The position peaked at $865 in Q3 2024. 170 funds tracked by Wall St. Rank hold VRDN as of Q2 2025.

  • Wolff Wiese Magana reported no remaining Viridian Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Wolff Wiese Magana sold 38 Viridian Therapeutics shares in Q2 2025, an estimated $513.
  • Wolff Wiese Magana first reported a position in Viridian Therapeutics in Q3 2024 and held it in 3 quarters.
  • Wolff Wiese Magana's Viridian Therapeutics position peaked at $865 in Q3 2024.
  • 170 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2025.

Based on Wolff Wiese Magana's 13F filing for Q2 2025, filed 17 Jul 2025.